Try HUABIO's Recombinant Antibodies: Reduced Pricing Only on Scientist.com

HUABIO is now offering trial sizes for their recombinant antibodies for $50, exclusively on Scientist.com. Find all of their available trial sizes...
Isabel Felix-chan
公開日
June 16, 2023

HUABIO is now offering trial sizes for their recombinant antibodies for $50, exclusively on Scientist.com. Find all of their available trial sizes here .

Background

Generated using in vitro cloning, recombinant antibodies are monoclonal antibodies where the genes encoding the antibody are inserted into expression vectors and then into host cells. This method of creating recombinant antibodies allows for reliable and scalable production, ensuring a stable and consistent supply of antibodies for research and therapeutic purposes. Recombinant antibodies can be modified to enhance their properties. Through genetic engineering techniques, researchers can introduce specific modifications to the antibody’s structure, such as altering the constant region or incorporating tags for purification and detection purposes. These modifications can improve the antibody’s stability, specificity, and binding affinity, leading to more effective and versatile applications.

Applications

Recombinant Antibodies are widely used in research, diagnostics, and therapeutics. In research, recombinant antibodies enable scientists to study the functions of specific proteins and their interactions within biological systems. They are also valuable tools in diagnostics, where they can detect and quantify disease markers with high sensitivity and specificity. In therapeutics, recombinant antibodies have emerged as powerful agents for targeted therapy, particularly in the field of cancer treatment, where they can selectively bind to cancer cells and trigger immune responses against them.

Advantages

Recombinant antibodies are artificially engineered antibodies that offer several advantages over traditional antibodies derived from animals or humans. They can be produced in large quantities and have a high degree of specificity and affinity for their target molecules. This makes them valuable tools for research, diagnostics, and therapeutics. They can be used to study the functions of specific proteins, identify biomarkers, and develop targeted therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. They can be modified to enhance their stability, half-life, and therapeutic efficacy. They can also be engineered to possess additional functions, such as drug delivery or imaging capabilities.

Find 10 of HUABIO’s top selling recombinant antibodies on Scientist.com below. Click here to view HUABIO’s full catalog.

Catalog Number Name Tested for Reacts with Trial Sizes Available? ET1601-10 Anti-Glucose Transporter GLUT1 Antibody [SA0377] WB, IF-Cell, IF-Tissue, IHC-P, FC Human, Mouse, Rat ET1609-76 Anti-Sodium Potassium ATPase Antibody [ST0533] WB, IF-Cell, IF-Tissue, IHC-P, FC Human, Mouse, Rat ET1702-06 Anti-Transferrin Receptor (CD71) Antibody [JF0956] WB, IHC-P, IP, FC Human, Mouse, Rat ET1601-9 Anti-CD9 Antibody [SA35-08] WB, IF-Cell, IF-Tissue, IHC-P, IP Human, Mouse, Rat Yes ET1611-87 Anti-TAPA1/CD81 Antibody [SN206-01] WB, IF-Cell, IHC-P, FC Human, Mouse, Rat Yes ET1703-63 Anti-TNF Receptor II Antibody [JM113-01] WB, IF-Cell, IF-Tissue, IHC-P, FC, IP Human, Mouse, Rat ET1610-93 Anti-NLRP3 Antibody [SC06-23] WB, IF-Cell, IF-Tissue, IHC-P, FC, IP Human, Mouse, Rat Yes ET1609-25 Anti-TOMM20 Antibody [ST04-72] WB, IF-Cell, IF-Tissue, IHC-P, FC, IP Human, Mouse, Rat Yes ET1605-41 Anti-V5 tag Antibody [SY30-01] WB ET1610-45 Anti-Wilms Tumor Protein Antibody [SC06-41] WB, IF-Cell, IF-Tissue, IHC-P, FC Human, Mouse Yes References https://www.huabio.com/pages/recombinant-antibodies https://www.huabio.com/blogs/news/the-power-of-recombinant-antibodies

Abstract molecular cluster with three connected blue-green spheres on a white background.

次のステップへ進む

1
2
3

Explore Suppliers

関連する専門知識を持つ信頼できるパートナーを探す

Review Capabilities

サービス、経験、実績を比較する

Start Your Project

つながり、協業を始める

執筆者
Isabel Felix-chan
この記事をシェアする

続きを読む

続きを読む